ASH 2023 | Comparing dasatinib-blinatumomab vs ponatinib-blinatumomab in newly diagnosed Ph+ B-ALL
Sabina Chiaretti, MD, PhD, University of Rome, Rome, Italy, shares insights into the GIMEMA ALL2820 trial (NCT04722848), a randomized, open-label multicenter Phase III study in adults with newly diagnosed Philadelphia chromosome-positive B-cell acute lymphoblastic leukemia (Ph+ B-ALL). The aim of the trial is to compare the combination of ponatinib and blinatumomab to the combination of dasatinib and blinatumomab, which is being explored in the GIMEMA LAL2116 (D-ALBA) study (NCT02744768). Early data indicate a lower rate of relapse in patients treated with ponatinib plus blinatumomab. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Incyte: Membership on an entity’s Board of Directors or advisory committees; Abbvie: Membership on an entity’s Board of Directors or advisory committees; Gilead: Membership on an entity’s Board of Directors or advisory committees; Pfizer: Membership on an entity’s Board of Directors or advisory committees; Amgen: Membership on an entity’s Board of Directors or advisory committees.
